Obesity Treatment - twenty30 health

USPTF on Kids with Obesity; GLP-1s on Brain Diseases; Financial Incentives to Lose Weight; Novel Amylin Drug Drives 8.6% Weight Loss at 16 Weeks

June 23, 2024 No Comments

AT A GLANCE The US Preventive Services Task Force published in JAMA a Recommendation Statement on Interventions for High Body Mass Index in Children and Adolescents. Simar Bajaj at NewScientist on GLP-1s’ unexpected effects on the brain, to treat depression, anxiety, addiction and Alzheimer’s. JAMA Pediatrics publishes the impact of financial incentives on improved outcomes of a dietary intervention among 126 adolescents with severe obesity. Zealand Pharma drug petrelintide, which targets the

Novo’s Semaglutide for Heart Failure; Biocon Leads India’s Generic GLP-1 Charge; I’m a Doctor on Ozempic; Cost-Effectiveness of Semaglutide Versus Endoscopic Sleeve

April 14, 2024 No Comments

AT A GLANCE Biocon Ltd. is leading India’s push to weight loss medications as patents lapse, unleashing generic supply for the global weight-loss market, from Bloomberg. STAT News reports European regulators ‘…have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.’ ‘I’m a doctor on Ozempic – it’s effective under one condition…’ says President and CEO of Philadelphia College of Osteopathic Medicine,

Anti-Obesity Meds for those with HIV; Medicare Approval Likely for Wegovy; Amazon Delivery of GLP-1 Meds; Obesity Treatment in Primary Care

March 17, 2024 No Comments

AT A GLANCE Nature journal reports ‘…People with HIV are the latest group to benefit from the new generation of anti-obesity drugs.’ STAT suggests FDA approval of Wegovy for heart benefits ‘…could provide a backdoor way to expand access to the drug for people on Medicare.’ Peter Loftus at The Wall Street Journal reveals those ‘…seeking a popular new weight-loss drug will have a new home-delivery option from

GLP-1 for Kidney Disease; FDA approves Wegovy for Cardiovascular Disease; Eli Lilly’s new Ad Campaign ahead of the Oscars; Obesity is South Africa’s New HIV Epidemic.

March 10, 2024 No Comments

AT A GLANCE Novo Nordisk’s FLOW trial of Ozempic demonstrates a ‘…24% reduction in the risk of kidney disease-related events…’ STAT reports on Novo Nordisk’s phase 1 trial of experimental oral medicine amycretin, with an average of 13.1% weight loss after 12 weeks. Reuters informs on Novo Nordisk market cap of $556 billion and had surpassed that of Tesla. The FDA approved ‘…a new indication for use

A Billion People Obese Worldwide; An Obesity Vaccine? – from Novo Nordisk and Vivani; Survodutide for Liver Disease; Bariatric Surgery Cures Diabetes

March 3, 2024 No Comments

AT A GLANCE STAT reports on Marcus Schindler, Novo’s chief scientific officer, who wants to ‘…make long-lasting GLP-1 molecules…’ with ‘…vaccine-like properties.’ NPM-115 and NPM-139 are miniature, subdermal GLP-1 implants from NASDAQ-listed company Vivani Medical, Inc. that provide once- or twice-yearly administration. STAT reports from a study in The Lancet that ‘…more than 1 billion people – or one in eight people worldwide –

Ro Prescribes Compounded Semaglutide; Tirzetapide for Fatty Liver; Obesity Center of Excellence; No-Zempic; AMG133 and Survodutide.

February 11, 2024 No Comments

AT A GLANCE STAT reports on Eli Lilly drug trial of tirzetapide as a treatment for the liver disease MASH. Business Insider reporter Shelby Livingston notes ‘…startup Ro just started prescribing “compounded” semaglutide, an alternative to Ozempic.’ Milliman, an international actuarial and consulting firm based in Seattle, Washington, explores the concept of an obesity center of excellence. No-zempic is leaving lots of people behind, from

Bariatric Surgery Numbers increase in 2022; Wegovy for Depression; Doctors have Fatphobia; Disparities in Obesity Meds; Increased GLP-1 Availability from Novo Nordisk

February 2, 2024 No Comments

AT A GLANCE Elaine Chen at STAT asks ‘Can Wegovy treat depression as well as obesity?’ The New York Times reports 750,000 state employees in North Carolina will no longer have insurance coverage for GLP-1 medications, as of April 1 2024. Novo Nordisk ‘…had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States…’ from Andrew Joseph at

Novo Marketing Spend Tops $1B; Obese Subjects in Clinical Trials; Social Isolation and Obesity; Preventing Muscle Mass Loss

January 28, 2024 No Comments

AT A GLANCE The UK’s Daily Mail newspaper notes Novo Nordisk ‘…has spent around $1 billion since 2018 to create the perception that sustained weight loss is only achievable by using the products.’ Scientific American questions if weight-loss drugs are sparking a risky new war on obesity? In counter to recent clinical trials, weight maintenance after stopping GLP-1 drug semaglutide may be possible, as per the Epic Research study.

Access to anti-obesity medications for Black Americans; Thanksgiving and the weight loss conversation; a four-monthly GLP-1 shot.

November 26, 2023 No Comments

AT A GLANCE Atiya Jordan recounts in Black Enterprise the disparity ‘…between the use of the anti-obesity and diabetes medication among Black people…’ while ‘…white people are four times more likely to receive a prescription.’ A new Tema Cardiovascular & Metabolic ETF, or exchange traded fund, seeks to invest ‘…in companies tackling diabetes, obesity and cardiovascular diseases…’ from Bansari Mayur Kamdar at Reuters. Alex Janin writes in

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

October 23, 2023 No Comments

AT A GLANCE DaVita Inc. issued a statement in response to Novo Nordisk in relation ‘…to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality.’ Retatrutide, an Eil Lilly drug yet to be approved by the FDA, boasting ‘…Phase 2 trial results that showed the drug led

Category: Obesity Treatment